Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

Clinical trial NCT00442650 · COMPLETED

Trial details

NCT number: NCT00442650
Sponsor: Merck KGaA, Darmstadt, Germany
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Moderate to Severe Psoriasis

Start date: 2004-01-01
Primary completion: 2005-12-01

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.